Medical Therapy for Myocardial Bridging
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests beta blockers and calcium channel blockers on adults with chest pain and myocardial bridges but no blocked arteries. These medications may help by relaxing heart muscles and improving blood flow, potentially reducing chest pain. Beta blockers and calcium channel blockers have been shown to be effective in treating angina pectoris, often used in combination to enhance therapeutic effects.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are using medications that have unsafe interactions with beta blockers or calcium channel blockers.
Is diltiazem generally safe for human use?
How does the drug combination of Diltiazem and Nebivolol work for myocardial bridging?
The combination of Diltiazem and Nebivolol is unique because Diltiazem, a calcium channel blocker, helps relax blood vessels and improve blood flow, while Nebivolol, a beta-blocker with nitric oxide-releasing effects, may help reduce coronary vasospasm. This dual approach could potentially offer a novel way to manage myocardial bridging by addressing both vessel relaxation and spasm reduction.12367
What evidence supports the effectiveness of the drug diltiazem for myocardial bridging?
Diltiazem, a drug that helps relax blood vessels, has been shown to be effective in treating various heart conditions, such as angina (chest pain) and dilated cardiomyopathy (a type of heart disease). It improves heart function and reduces symptoms, suggesting it may also help with myocardial bridging by improving blood flow and reducing heart strain.368910
Who Is on the Research Team?
Jennifer Tremmel, MD, MS
Principal Investigator
Stanford University
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized into one of three treatment arms: beta blocker (nebivolol), calcium channel blocker (diltiazem), or placebo for 30 days
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of angina and exercise capacity
What Are the Treatments Tested in This Trial?
Interventions
- Diltiazem
- Nebivolol
- Placebo
Diltiazem is already approved in United States, Canada, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor